0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Evaluation of Lippia scaberrima Sond. and Aspalathus linearis (Burm.f.) R. Dahlgren extracts on human CYP enzymes and gold nanoparticle synthesis: implications for drug metabolism and cytotoxicity

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Metabolism is an important component of the kinetic characteristics of herbal constituents, and it often determines the internal dose and concentration of these effective constituents at the target site. The metabolic profile of plant extracts and pure compounds need to be determined for any possible herb-drug metabolic interactions that might occur.

          Methods

          Various concentrations of the essential oil of Lippia scaberrima, the ethanolic extract of Lippia scaberrima alone and their combinations with fermented and unfermented Aspalathus linearis extract were used to determine the inhibitory potential on placental, microsomal and recombinant human hepatic Cytochrome P450 enzymes. Furthermore, the study investigated the synthesis and characterization of gold nanoparticles from the ethanolic extract of Lippia scaberrima as a lead sample. Confirmation and characterization of the synthesized gold nanoparticles were conducted through various methods. Additionally, the cytotoxic properties of the ethanolic extract of Lippia scaberrima were compared with the gold nanoparticles synthesized from Lippia scaberrima using gum arabic as a capping agent.

          Results

          All the samples showed varying levels of CYP inhibition. The most potent inhibition took place for CYP2C19 and CYP1B1 with 50% inhibitory concentration (IC 50) values of less than 0.05 µg/L for the essential oil tested and IC 50-values between 0.05 µg/L-1 µg/L for all the other combinations and extracts tested, respectively. For both CYP1A2 and CYP2D6 the IC 50-values for the essential oil, the extracts and combinations were found in the range of 1 – 10 µg/L. The majority of the IC 50 values found were higher than 10 µg/L and, therefore, were found to have no inhibition against the CYP enzymes tested.

          Conclusion

          Therefore, the essential oil of Lippia scaberrima, the ethanolic extract of Lippia scaberrima alone and their combinations with Aspalathus linearis do not possess any clinically significant CYP interaction potential and may be further investigated for their adjuvant potential for use in the tuberculosis treatment regimen. Furthermore, it was shown that the cytotoxic potential of the Lippia scaberrima gold nanoparticles was reduced by twofold when compared to the ethanolic extract of Lippia scaberrima.

          Supplementary Information

          The online version contains supplementary material available at 10.1186/s12906-024-04439-9.

          Related collections

          Most cited references43

          • Record: found
          • Abstract: not found
          • Article: not found

          Presenting Vancomycin on Nanoparticles to Enhance Antimicrobial Activities

            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Synthesis of silver nanoparticles using plants extract and analysis of their antimicrobial property

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The role of nanotechnology in the treatment of viral infections

              Infectious diseases are the leading cause of mortality worldwide, with viruses in particular making global impact on healthcare and socioeconomic development. In addition, the rapid development of drug resistance to currently available therapies and adverse side effects due to prolonged use is a serious public health concern. The development of novel treatment strategies is therefore required. The interaction of nanostructures with microorganisms is fast-revolutionizing the biomedical field by offering advantages in both diagnostic and therapeutic applications. Nanoparticles offer unique physical properties that have associated benefits for drug delivery. These are predominantly due to the particle size (which affects bioavailability and circulation time), large surface area to volume ratio (enhanced solubility compared to larger particles), tunable surface charge of the particle with the possibility of encapsulation, and large drug payloads that can be accommodated. These properties, which are unlike bulk materials of the same compositions, make nanoparticulate drug delivery systems ideal candidates to explore in order to achieve and/or improve therapeutic effects. This review presents a broad overview of the application of nanosized materials for the treatment of common viral infections.
                Bookmark

                Author and article information

                Contributors
                namrita.lall@up.ac.za
                Journal
                BMC Complement Med Ther
                BMC Complement Med Ther
                BMC Complementary Medicine and Therapies
                BioMed Central (London )
                2662-7671
                5 April 2024
                5 April 2024
                2024
                : 24
                : 152
                Affiliations
                [1 ]Department of Plant and Soil Sciences, University of Pretoria, ( https://ror.org/00g0p6g84) Pretoria, 0002 South Africa
                [2 ]Research Fellow, South African International Maritime Institute (SAIMI), Nelson Mandela University, ( https://ror.org/03r1jm528) Gqeberha, 6019 South Africa
                [3 ]School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, ( https://ror.org/00cyydd11) 70210 Kuopio, Finland
                [4 ]GRID grid.7327.1, ISNI 0000 0004 0607 1766, Nanostructures and Advanced Materials, , DSI-CSIR Nanotechnology Innovation Centre. Council for Scientific and Industrial Research, ; Pretoria, 0001 South Africa
                [5 ]Centre for Nanostructures and Advanced Materials, DSI-CSIR Nanotechnology Innovation Centre, Council for Scientific and Industrial Research, ( https://ror.org/05j00sr48) Pretoria, 0002 South Africa
                [6 ]School of Natural Resources, University of Missouri, ( https://ror.org/02ymw8z06) Columbia, MO USA
                [7 ]College of Pharmacy, JSS Academy of Higher Education and Research, ( https://ror.org/013x70191) Mysuru, Karnataka India
                [8 ]Senior Research Fellow, Bio-Tech R&D Institute, University of the West Indies, ( https://ror.org/03fkc8c64) Kingston, Jamaica
                Article
                4439
                10.1186/s12906-024-04439-9
                10996199
                38580936
                75db8f23-910a-4932-aefb-0603a14695b2
                © The Author(s) 2024

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

                History
                : 23 October 2023
                : 15 March 2024
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/501100001321, National Research Foundation;
                Award ID: 105169
                Award ID: 105169
                Award Recipient :
                Categories
                Research
                Custom metadata
                © BioMed Central Ltd., part of Springer Nature 2024

                aspalathus linearis,cytochrome p450,cytotoxicity,lippia scaberrima,nanoparticles

                Comments

                Comment on this article